The role and therapeutic effect of pitobrutinib

Pirtobrutinib (Pirtobrutinib, branded as Jaypirca, is a revolutionary drug that works by blocking an enzyme called Bruton's tyrosine kinase (BTK). BTK plays a key role in the development and signaling of B cells, especially in abnormal B cells in patients with mantle cell lymphoma (MCL). The abnormal activity of BTK promotes the unlimited proliferation of cancer cells. By precisely inhibiting the activity of BTK, Pitobrutinib is expected to slow down the progression of the disease and provide new treatment hope for patients who do not respond to traditional treatments or whose disease relapses.

In clinical trials, the therapeutic effect of pitobrutinib has been fully verified. One major study included 164 patients with MCL, with the primary analysis involving 90 patients who had previously been treated with a BTK inhibitor and whose condition was evaluable by scan. Of note, this study did not compare pitobrutinib to other treatments, but instead focused on evaluating the drug's efficacy in a specific patient population.

The study results showed that approximately57% of patients (ie, 51 out of 90 people) had a complete or partial response to pitobrutinib. This means that after treatment, these patients either have no residual signs of cancer or have a significant reduction in the amount of cancer. Even more encouraging, about 19% of patients, or 17 out of 90, achieved a complete response, with all signs of cancer in their bodies eliminated. Furthermore, these treatment responses lasted an average of 18 months, demonstrating the durable efficacy of pitobrutinib in controlling disease progression.

The reason why Pitobrutinib can achieve such remarkable efficacy inMCL treatment is mainly due to its non-covalent and reversible BTK inhibition properties. Compared with traditional covalent BTK inhibitors, pitobrutinib can target BTK more precisely and maintain inhibitory activity even in the presence of mutations in the BTK kinase domain, thereby overcoming resistance to traditional BTK inhibitors. This property makes pitobrutinib an ideal option for patients who have failed or relapsed from prior BTK inhibitor therapy.

In addition to its remarkable efficacy, pitobrutinib has a good tolerability and safety profile. In clinical trials, although some patients experienced adverse reactions such as fatigue, diarrhea, and musculoskeletal pain, most reactions were mild to moderate and could be effectively controlled through appropriate dose adjustment and management.

In summary, pitobrutinib, as a newBTK inhibitor, provides a new treatment option for MCL patients. By precisely inhibiting the activity of BTK, it is expected to slow down the progression of the disease and improve the quality of life of patients. With the in-depth research on this drug and the promotion of clinical application, it is believed that pitobrutinib will bring hope and good news to more MCL patients in the future.

xa0

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca